Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that

The 20-foot wide mansion was built in 1869 along with three others on East 74th Street, and was significantly redesigned in 1919 by architect George Blum, who added its historically significant limestone facade, French windows and a green-tiled roof.

Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the field of precision medicine,

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (NasdaqGS:LRCX) from Neutral to Overweight. Analyst Price Forecast Suggests 13.99% Upside As of January 28,

Cantor Fitzgerald adjusted its price target for Teradyne stock (NASDAQ:TER), bringing it down to $150 from the previous $160, while still maintaining an Overweight rating on the company's shares. Currently trading at $115.

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish China stance.

Donald Trump's commerce secretary nominee said Wednesday that he favors "across-the-board" tariffs and a country-based approach rather than targeting products, signaling a hawkish China stance as he a

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. Analyst Price Forecast Suggests 87.91% Upside As of January 29,

Cantor Fitzgerald CEO and Commerce Secretary nominee Howard Lutnick became visibly emotional at his confirmation hearing Wednesday as he recalled the more than 650 employees — including his